The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Results from PI/PII Studies of BBI608, BBI503 Presented at ASCO Annual Meeting: DSP
June 9, 2014
- AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
- Malignant STS Treatment Trabectedin Achieves Primary Endpoint in Domestic PII Clinical Trial: Taiho
June 6, 2014
- Nihon Chouzai to Provide Online Daily Pharmacy Prescription Trend Info.
June 6, 2014
- Combination Therapy of Avastin, Tarceva Significantly Prolongs PFS in PII Study: Roche
June 6, 2014
- Sales of 26 Pharma Companies Up 10.3% Driven by Strong Overseas Sales
June 5, 2014
- Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
- Sysmex Inostics, Merck Serono of Germany to Codevelop CoDx for Erbitux for Treatment of Colon Cancer
June 5, 2014
- Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
June 4, 2014
- Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
June 4, 2014
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
- Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
June 2, 2014
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
- Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
June 2, 2014
- Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
June 2, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…